Libertyville, IL, United States of America

Lawrence A Black

This inventor holds 41 USPTO granted patents and 16 published patent applications, plus 6 CIPO patents and 10 EPO patents, primarily in Phosphodiesterase Inhibitors. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Abbvie Deutschland Gmbh and Co Kg. Active years: 1988-2021.

USPTO Granted Patents = 41 (Patent Applications = 16)

% Patents Active = 53.7

CIPO Patents = 6 (Patent Applications = 13)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 5.2

ph-index = 8

Forward Citations = 236(Granted Patents)

Location History:

Vernon Hills, IL (US) (1988 - 1996)
Libertyville, IL (US) (2001 - 2015)
North Chicago, IL (US) (2016 - 2017)
Lahaina, HI (US) (2020 - 2021)

Company Filing History:

24 out of 4,186

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

patents

4. 4 out of 16,339

E.i. Dupont De Nemours and Company

patents

5. 1 out of 6

Calico Life Sciences LLC

patents

6. 1 out of 206

The Dupont Merck Pharmaceutical Company

patents

where one patent can have more than one assignee

Years Active: 1988-2021

Loading Chart...

Areas of Expertise:

Phosphodiesterase Type 10A

Integrated Stress Pathway

Histamine-3 Receptor

Bicyclic Amines

Cyclopropyl Derivatives

Macrocyclic Compounds

Amino Heterocycles

Prostaglandin Inhibitors

Antifibrillatory Agents

Pyrimidine Derivatives

Isoquinolines

Thieno Compounds

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10913727 - Modulators of the integrated stress pathway (2021-02-09),

2. 10864196 - Modulators of the integrated stress pathway (2020-12-15),

3. 10836725 - Modulators of the integrated stress pathway (2020-11-17),

4. 9790203 - Inhibitor compounds of phosphodiesterase type 10A (2017-10-17),

5. 9657034 - Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors (2017-05-23),

6. 9273068 - Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A (2016-03-01),

7. 9138494 - Radiolabeled PDE10A ligands (2015-09-22),

8. 9108948 - Cyclopropyl amine derivatives (2015-08-18),

9. 8829041 - Cyclopropyl amine derivatives (2014-09-09),

10. 8796297 - 4-substituted-2-amino-pyrimidine derivatives (2014-08-05),

11. 8735411 - Macrocyclic benzofused pyrimidine derivatives (2014-05-27),

12. 8580968 - Benzothiazole and benzooxazole derivatives and methods of use (2013-11-12),

13. 8436005 - Macrocyclic pyrimidine derivatives (2013-05-07),

14. 8399468 - Octahydro-pyrrolo[3,4-B]pyrrole derivatives (2013-03-19),

15. 8278313 - Macrocyclic spiro pyrimidine derivatives (2012-10-02),

Title: Innovations and Contributions of Lawrence A. Black

Introduction

Lawrence A. Black is a prominent inventor based in Libertyville, IL, who has made significant contributions to the field of biomedical research and pharmaceuticals. With a total of 41 patents to his name, he has been instrumental in advancing methodologies and solutions to address various health-related challenges.

Latest Patents

Among his latest innovations are patents related to "Modulators of the Integrated Stress Pathway." These patents detail compounds, compositions, and methods that are valuable for modulating the integrated stress response (ISR) and for treating related diseases, disorders, and conditions. This research holds considerable promise in mitigating the impacts of stress-related health issues.

Career Highlights

Lawrence A. Black has had a notable career, working with leading companies in the pharmaceutical and biotechnology sectors. He has notably been associated with Abbott Laboratories Corporation and AbbVie Inc., where he has contributed to pioneering research and development efforts resulting in valuable patents.

Collaborations

Throughout his career, Lawrence has collaborated with esteemed colleagues, including Marlon D. Cowart and Huaqing Liu. These collaborations have enriched his research endeavors and expanded the scope of his innovations within the industry.

Conclusion

Lawrence A. Black stands out as an influential inventor whose work continues to drive progress in biomedical science. With his substantial portfolio of patents, he has significantly impacted the understanding and treatment of stress-related disorders, marking him as a key figure in the realm of innovative research and development.